Donor (allogeneic) stem cell transplants
Stem cell transplants that use donor stem cells are called allogeneic stem cell transplants. Allogeneic stem cell transplants are sometimes used in the treatment of lymphoma to replace damaged or destroyed stem cells with healthy ones.
We have separate information on stem cell transplants that use your own stem cells (autologous stem cell transplants).
On this page
What is a donor (allogeneic) stem cell transplant?
What does an allogeneic stem cell transplant involve?
What is a donor (allogeneic) stem cell transplant?
A stem cell transplant is a procedure that replaces damaged or destroyed stem cells (cells in your bone marrow that make new blood cells) with healthy stem cells.
‘Allogeneic’ means something that comes from a different person, as opposed to something that comes from you. An allogeneic stem cell transplant is a stem cell transplant that uses stem cells from a donor.
You might also hear an allogeneic stem cell transplant referred to as an ‘allograft’.
Watch Kat share her experience of an allogeneic stem cell transplant. (This video refers to Lymphoma Association, our charity’s name before becoming Lymphoma Action). You can also read Kat’s story, including an update since this video.
Who might have a donor stem cell transplant?
Most people with lymphoma do not need a stem cell transplant.
You might have a stem cell transplant if you need high-dose anti-cancer treatment. High-dose treatment aims to destroy lymphoma cells but it can also destroy your stem cells. This stops you making the new blood cells your body needs. A stem cell transplant allows you to have high-dose treatment because it replaces the stem cells damaged by the treatment.
An allogeneic stem cell marrow transplant can also help fight the lymphoma directly. The donor stem cells build a ‘new’ immune system. The new immune cells can recognise lymphoma cells as foreign and help to get rid of them. They can also help prevent the lymphoma coming back (relapsing). This effect is known as the ‘graft-versus-tumour effect’ or ‘graft-versus-lymphoma effect’.
High-dose treatment with an allogeneic stem cell transplant is only used in certain circumstances. In some situations, they can increase your chance of having a long-lasting remission (no evidence of lymphoma). However, there is a risk of serious side effects and complications. Your medical team should tell you what is involved and if there are any other treatment options.
Below we list some of the situations when an allogeneic stem cell transplant might be recommended. Not everybody with these types of lymphoma needs a stem cell transplant – and there might be other situations where your doctor feels a stem cell transplant is the best option for you.
You might have an allogeneic stem cell transplant:
- if you have lymphoma that comes back (relapses) after a self (autologous) stem cell transplant
- if your lymphoma doesn’t respond to your first treatment (refractory lymphoma)
- if you have adult T-cell lymphoma (ATL) as part of your first-line treatment
- if you have chronic lymphocytic leukaemia (CLL) that has transformed to high-grade lymphoma (Richter’s transformation) as first-line treatment
- rarely, if you have Waldenström’s macroglobulinaemia that comes back (relapses) after previous treatment.
A stem cell transplant is an intensive form of treatment and you have to be well enough to have one. It can take many months to fully recover. Your medical team consider many factors before recommending a stem cell transplant.
You should consider the possible risks and benefits of having an allogeneic stem cell transplant very carefully. Ask as many questions as you need to reach a decision. You might want to use our list of suggested questions to ask your medical team to help you.
What does an allogeneic stem cell transplant involve?
There are a number of steps involved in an allogeneic stem cell transplant:
- you have tests and scans to make sure you are fit enough to have the treatment
- your transplant coordinator organises a search for a suitable stem cell donor (Anthony Nolan’s video guide shows how a donor is found and what happens during the process)
- you have high-dose anti-cancer treatment in hospital (this is also called conditioning treatment)
- the donor stem cells are given to you to replace your stem cells that have been destroyed by the high-dose anti-cancer treatment
- you stay in hospital while your blood counts to recover.
We have detailed information about each step on our page on having a stem cell transplant.
I waited anxiously for the donor cells to start grafting into my body. It was an amazing feeling when the counts started to climb up from zero. I started to think there would be a time when I could be outside again.
What are the risks of an allogeneic stem cell transplant?
The most serious risks of allogeneic stem cell transplants are:
- graft-versus-host disease (GvHD)
- a high risk of infection
- side effects of your high-dose anti-cancer treatment
- graft failure.
You are also at risk of developing late effects (health problems that may develop months or years after your treatment).
Graft-versus-host disease
Graft-versus-host disease (GvHD) is a common complication of an allogeneic stem cell transplant. It happens when the new immune system that grows from the donor cells (the ‘graft’) recognises the other cells in your body (the ‘host’) as foreign, and attacks them.
This effect is useful when it attacks your lymphoma cells, but it can also attack healthy tissues. This can cause serious side effects. Most of the time, GvHD causes mild-to-moderate symptoms, but occasionally, it can be severe and even life-threatening. Before and after your transplant, you are given treatment (immunosuppressant drugs) to reduce your risk of developing GvHD. Your transplant team monitors you closely for any signs of GvHD so they can treat it as early as possible if it develops.
GvHD is classed as ‘acute’ or ‘chronic’ depending on when you experience it and the signs and symptoms you have.
Acute GvHD
Acute GvHD typically develops within 100 days of your transplant – although it might develop later, particularly if you’ve had reduced-intensity conditioning treatment or are given donor lymphocytes after transplant.
Up to half of all people who have an allogeneic stem cell transplant develop some degree of acute GvHD. It mainly affects the skin, the gut and the liver. It can cause:
- a sore, itchy rash, often on the hands, feet, ears and chest, although it can spread to the whole body
- feeling sick (nausea), being sick (vomiting), tummy pain and weight loss
- diarrhoea, which can be watery or bloody
- fever
- jaundice (a build-up of a chemical called ‘bilirubin’, which can make the whites of your eyes and your skin look yellow).
Acute GvHD is graded from 0 (none) to 4 (very severe) based on the symptoms you have. Grading helps your doctor to decide what treatment to give you.
Chronic GvHD
Chronic GvHD generally develops more than 100 days after your transplant. It is most likely to develop in the first year after your transplant, but it can happen later. It affects around half of all people who experienced acute GvHD but it can develop even if you didn’t have acute GvHD.
Chronic GvHD most often affects the mouth, skin, gut and liver. It can also affect other areas, such as your eyes, joints, lungs and genitals. The features of chronic GvHD are different from those of acute GvHD.
Symptoms of GvHD can include:
- skin rashes, flaking or itchy skin, changes in skin tone or texture, tightening of the skin
- dry or irritated eyes
- dry or sore mouth
- thinning of your hair
- vaginal dryness
- indigestion, diarrhoea, nausea, vomiting or unexplained weight loss.
Your doctor should assess you for GvHD regularly as part of your follow-up. For each part of your body affected by chronic GvHD, they might give you a score between 0 (no impact) and 3 (severe impact) based on the impact your symptoms have on your daily life. This helps them decide on the best treatment for you.
If you have any signs of GvHD, you will have tests to find out what areas of your body are affected and how severe it is. These might include blood tests and scans.
Prevention and treatment of GvHD
Before and after your transplant, you have drugs to dampen your immune system (immunosuppressant drugs) to try to prevent GvHD developing or to limit the effects of it if it does develop. They are often started during your conditioning treatment.
The most common drugs used to prevent GvHD are:
- methotrexate, a type of chemotherapy given through a drip into a vein. You usually have it on days 1, 3, 6 and 11 after your stem cell infusion.
- ciclosporin (sometimes spelt cyclosporin), an immunosuppressant medicine. You have it through a drip into a vein every day at first and then as tablets (orally) once your blood counts have recovered. You carry on taking it when you go home after your transplant. The dose is gradually reduced as your new immune system becomes less reactive to your own body tissues. This might take several years.
- mycophenolate mofetil (often referred to as MMF), an immunosuppressant medicine. You have it through a drip into a vein every day at first and then as oral tablets.
Some transplant centres use different drugs, particularly for people who have reduced-intensity conditioning or who only have a partially matched stem cell donor.
If you develop GvHD, your doctor might increase your immunosuppressant drugs. If this is not effective, you might need high doses of steroids to suppress your immune system further. You also have treatments to help control your symptoms of GvHD. These vary depending on the parts of your body that are affected.
If steroids do not control GvHD, there are a range of other treatment options. Your doctor chooses your treatment based on your individual circumstances.
Because treatment for GvHD suppresses your immune system, it can increase your risk of developing infections. Your transplant team tries to find the right balance of medications that allows your immune system to fight infections without attacking healthy cells.
As time goes on, your new immune system usually becomes more tolerant to your host cells and you can gradually come off your immunosuppressant drugs. Sometimes GvHD can develop or flare up when your immunosuppressant drugs are reduced, so your medical team monitor you closely. If GvHD develops or comes back, you restart the immunosuppressant drugs.
The charity Anthony Nolan produce a booklet about GvHD.
Risk of infection
After an allogeneic stem cell transplant, you have very low blood counts for a few weeks. Having a low white blood cell count, especially a type of blood cell called ‘neutrophils’ (neutropenia), puts you at very high risk of developing an infection.
While you are in hospital, your medical team take precautions to reduce your risk of infection. They also monitor you closely for any signs of infection. Although taking precautions can reduce your risk of infection, you cannot avoid all sources of infection. Infections can be treated, particularly if they are caught early. Most people develop infections after an allogeneic stem cell transplant.
In the first month or so after an allogeneic stem cell transplant, you are at highest risk of developing bacterial infections, such as bloodstream infections, pneumonia, digestive system infections or skin infections.
In the next few months, you are most at risk of developing viral infections. These might be viruses that were lying dormant in your body before your transplant that may flare up when your immune system is low. They don’t always cause symptoms. You have regular blood tests after your transplant to make sure you don’t have a flare-up of a viral infections, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV). In many cases, if your blood tests show an infection is present – even if you have no symptoms – you have treatment with antiviral drugs. You might need more than one course of treatment.
Your blood counts start to rise between 2 to 4 weeks after an allogeneic stem cell transplant. However, it can take many months, or sometimes even years, for your immune system to recover fully, especially if you are still taking immunosuppressant drugs to prevent GvHD.
When you go home, your team should tell you what signs of infection to look out for and who to contact if you are worried you might have an infection.
Contact your medical team immediately if you have any signs of infection.
Side effects of conditioning treatment
You are likely to experience side effects from your high-dose anti-cancer treatment (‘conditioning’ treatment). We have separate information on the most common side effects of lymphoma treatments, including practical tips on how to cope with them. You might find the following pages particularly helpful:
- dry, sore mouth (oral mucositis)
- anaemia (low red blood cell count)
- thrombocytopenia (low platelet level)
- sickness (nausea and vomiting)
- bowel problems (diarrhoea, constipation, wind).
Graft failure
Graft failure occurs if the transplanted stem cells fail to settle in your bone marrow and make new blood cells. This means your blood counts do not recover, or they begin to recover but then go down again. Graft failure is rare after an allogeneic stem cell transplant, especially if your donor is a good match. Your medical team monitors your blood counts closely. If your graft does fail, you might be treated initially with growth factors or hormones. These encourage the stem cells in your bone marrow to produce more cells. You might need a second stem cell transplant, either from the same stem cell donor or a different one.
Post-transplant lymphoproliferative disorder
You might be at risk of developing post-transplant lymphoproliferative disorder (PTLD) – lymphomas that can develop in people who are taking immunosuppressant drugs after a transplant. However, PTLD is rare. Most people who have had transplants do not develop PTLD. Your transplant team will talk to you about your individual risk and any signs or symptoms you should look out for.
Late effects
Late effects are health problems that may develop months or years after your lymphoma treatment. Most transplant centres have dedicated late effects services that offer screening programmes to detect late effects as early as possible. This gives you the best chance of being treated successfully if you develop any late effects.
Your medical team should tell you what late effects you may be at risk from and what you can do to reduce your risk of developing them. For more information, see our page on late effects of lymphoma treatment.
Follow-up after an allogeneic stem cell transplant
Most people go home 2 to 3 weeks after having their stem cell transplant. However, it can be longer, particularly if you develop a serious infection or other complications. Your risk of complications is highest in the first few weeks after your transplant but it can take many months, sometimes even years, for your immune system to recover fully.
After you go home, you are usually seen in the clinic every week at first to check your blood counts are recovering well. You have blood tests to check your blood counts and to measure your virus levels. Your doctor also checks for any signs of GvHD. You might need blood transfusions if your red blood cells or platelets are low.
If your new immune system is not making as many cells as it should be, you might have a transfusion of white blood cells from your donor. This is called a ‘donor lymphocyte infusion’ (DLI). It helps boost the graft-versus-lymphoma effect. This can happen at any point after the transplant but it is most common during the first couple of years.
Coming home from hospital was quite bewildering. I felt like I was being cut loose and that feeling made me nervous.
Around 3 months after your transplant, if you are recovering well, your appointments usually go down to about once a month. You might be referred back to your local hospital with less frequent visits to your transplant centre. You might have a CT scan or PET/CT scan to see how the lymphoma has responded to the treatment. If you had lymphoma in your bone marrow, you might also have a bone marrow biopsy.
You have regular tests to check on your recovery. Gradually, you have longer between your follow-up appointments. Your follow-up appointments are to check that your lymphoma has not come back (relapsed) and to look out for any signs of GvHD or late effects (side effects that develop months or years after treatment). They are also an opportunity to ask any questions you might have.
When you have a stem cell transplant, you lose your immunity to diseases you were vaccinated against before your transplant. This includes the vaccinations you had as a child. Around 6 months to a year after your transplant, you should be offered a revaccination programme. You should also have any recommended annual vaccinations such as the flu and COVID vaccines.
Recovery after an allogeneic stem cell transplant
Although you might be allowed home a couple of weeks after an allogeneic stem cell transplant, it can take several months to a year or even more for you to recover completely. This can be a difficult time physically and emotionally. You might find our information on living with and beyond lymphoma helpful.
When you first go home, you will be on several treatments to prevent GvHD and infections. Your blood counts are also likely to be lower than normal. Follow any precautions your medical team recommends to help you stay well.
- Make sure you know how to reduce your risk of getting an infection and what signs to look out for. Your medical team should give you numbers to call at any time of day if you are worried.
- If you have low platelet levels (thrombocytopenia), you are at increased risk of bruising and bleeding. Take precautions to avoid injuring yourself and contact your medical team if you have any signs of bleeding.
- Contact your medical team if you develop any symptoms of GvHD.
It is common to have to go back into hospital for treatment in the weeks and months that follow your transplant but as time goes on, your risk of serious complications decreases.
During this time, you are also likely to be experiencing side effects from your high-dose treatment. You mightfeel unwell and very tired. Give yourself time to recover. It usually takes around a year to recover from an allogeneic stem cell transplant.
Listen to our podcast on stem cell transplants
In this podcast, John Murray, Advanced Practitioner in Bone Marrow Transplant, and Angie Leather, Lead Nurse for Transplant and Haematology, talk about the role of stem cell transplants, when they are used and the important differences between autologous (self) and allogeneic (donor) stem cell transplants. This podcast includes discussions around this often very difficult subject, and contains information on side effects and treatment outcomes that may be potentially distressing.
Trusted Information
-
Alazzam A, et al. The Role of Allogeneic Stem Cell Transplantation in Adult Patients With Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Oncology Volume, 2025. 19:1–9.
-
Blair SM, et al. Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer, 2020. 126: 1837–1855.
-
British Society of Blood and Marrow Transplantation and cellular therapy, 2024. Indications. Accessed October 2025.
-
Fox CP, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma):a British Society for Haematology Guideline. British Journal of Haematology, 2022. 196:507–522.
-
Greco R, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplantation, 2025. 60: 1499–1525.
-
Gribben JG. The role of stem cell transplant for lymphoma in 2017. Hematological Oncology, 2017. 35(S1): 25–29.
-
Hilal T and Mountjoy LJ. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B‑Cell Lymphoma: Evolving Role in the Era of CAR T‑Cell Therapy. Current Oncology Reports, 2023. 25: 599–607.
-
National Institute for Health and Care Excellence, 2016. Non-Hodgkin’s lymphoma: diagnosis and management: NG52. Accessed October 2025.
-
NHS Commissioning Board Clinical Reference Group for Blood and Marrow Transplant (BMT). Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages). NHS Commissioning Board, 2021. Accessed October 2025.
-
Sureda A, et al. (eds). The EBMT Handbook, 8th edition. Springer, 2024.
-
UK Paediatric BMT Group. Indications for HSCT in Children, 2022. Accessed October 2025.